Effect of lipegfilgrastim administration as prophylaxis of chemotherapy-induced neutropenia on dose modification and incidence of neutropenic events: real-world evidence from a non-interventional study in Belgium and Luxembourg.
OBJECTIVES: This study evaluated the effect of lipegfilgrastim, a glycopegylated granulocyte-colony stimulating factor, used as primary (PP) or secondary prophylaxis (SP) on chemotherapy (CT) treatment modifications, as well as the incidence of CT-induced neutropenic events in adult patients receiving cytotoxic CT with or without biological therapy (BT) for solid and hematological tumors, in routine clinical practice. Other objectives were to characterize the population of lipegfilgrastim-treated cancer patients and safety assessment. METHODS: This phase 4, prospective, observational study was... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2021 |
Verlag/Hrsg.: |
Taylor & Francis
|
Schlagwörter: | Lipegfilgrastim / chemotherapy dose modification / chemotherapy-induced neutropenia / febrile neutropenia / real-world evidence |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26994275 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://hdl.handle.net/2078.1/219362 |